President Trump's planned 100% tariff on imported pharmaceuticals, set to begin next week, could lead to higher U.S. consumer prices. However, exemptions for generic drugs and companies with U.S. manufacturing facilities may significantly mitigate the impact. Major drugmakers like Novartis and Roche anticipate minimal disruption due to existing or planned domestic production. Analysts suggest most pharmaceutical products may be excluded, limiting the "meaningful commercial hit" initially feared.

Prepared by Christopher Adams and reviewed by editorial team.